Geneva, Jan. 12 -- International Clinical Trials Registry received information related to the study (ChiCTR2500115167) titled 'Exploratory clinical study on preserving organs in patients with stage II-III non-small cell lung cancer(The Future Star)' on Dec. 23, 2025.
Study Type: Interventional study
Study Design:
Parallel
Primary Sponsor: Jiangsu Cancer Hospital
Condition:
Non-small cell lung cancer
Intervention:
Group A-R:In the neoadjuvant stage, almonertinib (for 18 weeks) + pemetrexed + carboplatin (every 3 weeks, for 4 cycles) ? After image-based assessment ? If the tumor shrinks by more than 80%, randomization?radiotherapy ? In the adjuvant stage, almonertinib (for 3 years)
Group A-S:In the neoadjuvant stage, almonertinib (f...